MicroRNA-21 promotes the progression of peritoneal fibrosis through the activation of the TGF-?/Smad signaling pathway: An in vitro and in vivo study Retraction in /10.3892/ijmm.2020.4510

Ma,Ya-Li; Chen,Fang; Yang,Su-Xia; Chen,Bao-Ping; Shi,Jun

doi:10.3892/ijmm.2017.3268

MicroRNA-21 promotes the progression of peritoneal fibrosis through the activation of the TGF-?/Smad signaling pathway: An in vitro and in vivo study

Retraction in: /10.3892/ijmm.2020.4510

Authors:
- Ya-Li Ma
- Fang Chen
- Su-Xia Yang
- Bao-Ping Chen
- Jun Shi
View Affiliations

Affiliations: Department of Nephrology, Huaihe Hospital of Henan University, Kaifeng, Henan 475000, P.R. China
Published online on: November 17, 2017 https://doi.org/10.3892/ijmm.2017.3268
Pages: 1030-1038

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to explore the roles of microRNA-21 (miR‑21) and the transforming growth factor-β (TGF-β)/Smad signaling pathway in the development of peritoneal fibrosis (PF). First, dialysis effluents from 30 patients with PF were collected, and after the establishment of a mouse model of PF, hematoxylin and eosin (H&E) and Masson's staining were used to observe peritoneal tissues, inflammatory cells and blood vessels. High glucose was used to stimulate human peritoneal mesothelial cell lines and these stimulated cells were then transfected with miR‑21 inhibitor. Immunofluorescence microscopy was applied for the observation of the transfected cells. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression of miR‑21, and RT-qPCR and western blot analysis were used to detect the mRNA and protein expression of Zonula occludens-1 (ZO-1), TGF-β, Smad, vimentin and connective-tissue growth factor (CTGF). The mRNA and protein expression levels TGF-β, Smad-3, vimentin and CTGF were elevated, while ZO-1 mRNA and protein expression was decreased with the prolonged duration of dialysis treatment in the patients with PF. The experiments using the mouse model of PF revealed that the peritoneal connective tissue was thickened, while the numbers of inflammatory cells and blood vessels were increased. The expression levels of miR‑21, and the mRNA and protein expression levels of TGF-β, Smad-3, vimentin and CTGF were increased over time, whereas the mRNA and protein expression levels ZO-1 constantly decreased in the mice in the experimental group. Moreoever, the expression of miR‑21 positively correlated with the expression levels of TGF-β, Smad-3, vimentin and CTGF, while it negatively correlated with the expression of ZO-1. The results of H&E and Masson's staining revealed that miR‑21 expression was associated with the degree of PF. These findings thus indicate that miR‑21 promotes the progression of PF through the activation of the TGF-β/Smad signaling pathway.

View Figures

View References

1	Chou CY, Wang SM, Liang CC, Chang CT, Liu JH, Wang IK, Hsiao LC, Muo CH, Chung CJ and Huang CC: Peritoneal Dialysis is associated with a netter survival in cirrhotic patients with chronic kidney disease. Medicine (Baltimore). 95:e24652016. View Article : Google Scholar
2	Bowen T: A role for fibrocytes in peritoneal fibrosis? Perit Dial Int. 32:4–6. 2012. View Article : Google Scholar : PubMed/NCBI
3	Stavenuiter AW, Farhat K, Vila Cuenca M, Schilte MN, Keuning ED, Paauw NJ, ter Wee PM, Beelen RH and Vervloet MG: Protective effects of paricalcitol on peritoneal remodeling during peritoneal dialysis. BioMed Res Int. 2015:4685742015. View Article : Google Scholar : PubMed/NCBI
4	de Lima SM, Otoni A, Sabino AP, Dusse LM, Gomes KB, Pinto SW, Marinho MA and Rios DR: Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis. Clin Chim Acta. 421:46–50. 2013. View Article : Google Scholar : PubMed/NCBI
5	Kawanishi K, Honda K, Tsukada M, Oda H and Nitta K: Neutral solution low in glucose degradation products is associated with less peritoneal fibrosis and vascular sclerosis in patients receiving peritoneal dialysis. Perit Dial Int. 33:242–251. 2013. View Article : Google Scholar :
6	Hung KY, Wu KD and Tsai TJ: In vitro study of peritoneal fibrosis. Perit Dial Int. 27(Suppl 2): S72–S75. 2007.PubMed/NCBI
7	Duan WJ, Yu X, Huang XR, Yu JW and Lan HY: Opposing roles for Smad2 and Smad3 in peritoneal fibrosis in vivo and in vitro. Am J Pathol. 184:2275–2284. 2014. View Article : Google Scholar : PubMed/NCBI
8	Li Z, Zhang L, He W, Zhu C, Yang J and Sheng M: Astragalus membranaceus inhibits peritoneal fibrosis via monocyte chemoattractant protein (MCP)-1 and the transforming growth factor-β1 (TGF-β1) pathway in rats submitted to peritoneal dialysis. Int J Mol Sci. 15:12959–12971. 2014. View Article : Google Scholar : PubMed/NCBI
9	Ghosh AK, Nagpal V, Covington JW, Michaels MA and Vaughan DE: Molecular basis of cardiac endothelial-to-mesenchymal transition (EndMT): Differential expression of microRNAs during EndMT. Cell Signal. 24:1031–1036. 2012. View Article : Google Scholar : PubMed/NCBI
10	Lan HY: Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. Int J Biol Sci. 7:1056–1067. 2011. View Article : Google Scholar :
11	Lan HY: Smads as therapeutic targets for chronic kidney disease. Kidney Res Clin Pract. 31:4–11. 2012. View Article : Google Scholar : PubMed/NCBI
12	van Bommel EF, van Spengler J, van der Hoven B and Kramer P: Retroperitoneal fibrosis: report of 12 cases and a review of the literature. Neth J Med. 39:338–345. 1991.PubMed/NCBI
13	Dou XR, Yu XQ, Li XY, Chen WF, Hao WK, Jia ZJ, Peng WX, Wang X, Yin PD, Wang WJ and Zheng ZH: The role of TGF-beta1/Smads in the development of peritoneal fibrosis induced by high glucose peritoneal dialysate and LPS. Zhonghua Yi Xue Za Zhi. 85:2613–2618. 2005.PubMed/NCBI
14	Lü ZD, Xu HM, Wang HB, Kong B, Li JG, Li FN and Song YM: Effect of peritoneal fibrosis induced by transforming growth factor-beta 1 on the adhesion of gastric cancer cell. Zhonghua Yi Xue Za Zhi. 92:1698–1701. 2012.In Chinese.
15	Vassiliadis E, Oliveira CP, Alvares-da-Silva MR, Zhang C, Carrilho FJ, Stefano JT, Rabelo F, Pereira L, Kappel CR, Henriksen K, et al: Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res. 4:403–414. 2012.PubMed/NCBI
16	Lan HY and Chung AC: TGF-β/Smad signaling in kidney disease. Semin Nephrol. 32:236–243. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zhong X, Chung AC, Chen HY, Meng XM and Lan HY: Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol. 22:1668–1681. 2011. View Article : Google Scholar : PubMed/NCBI
18	Meng XM, Huang XR, Xiao J, Chung AC, Qin W, Chen HY and Lan HY: Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int. 81:266–279. 2012. View Article : Google Scholar
19	Kok HM, Falke LL, Goldschmeding R and Nguyen TQ: Targeting CTGF, EGF and PDGF pathways to prevent progression of kidney disease. Nat Rev Nephrol. 10:700–711. 2014. View Article : Google Scholar : PubMed/NCBI
20	Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et al: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 456:980–984. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lee UE and Friedman SL: Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 25:195–206. 2011. View Article : Google Scholar : PubMed/NCBI
22	Mormone E, George J and Nieto N: Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact. 193:225–231. 2011. View Article : Google Scholar : PubMed/NCBI
23	Liang H, Zhang C, Ban T, Liu Y, Mei L, Piao X, Zhao D, Lu Y, Chu W and Yang B: A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol. 44:2152–2160. 2012. View Article : Google Scholar : PubMed/NCBI
24	Wang T, Zhang L, Shi C, Sun H, Wang J, Li R, Zou Z, Ran X and Su Y: TGF-β-induced miR-21 negatively regulates the antiproliferative activity but has no effect on EMT of TGF-β in HaCaT cells. Int J Biochem Cell Biol. 44:366–376. 2012. View Article : Google Scholar
25	Zhu H, Luo H, Li Y, Zhou Y, Jiang Y, Chai J, Xiao X, You Y and Zuo X: MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression. J Clin Immunol. 33:1100–1109. 2013. View Article : Google Scholar : PubMed/NCBI
26	Yao Q, Cao S, Li C, Mengesha A, Kong B and Wei M: Micro-RNA-21 regulates TGF-β-induced myofibroblast differentiation by targeting PDCD4 in tumor-stroma interaction. Int J Cancer. 128:1783–1792. 2011. View Article : Google Scholar
27	Butz H, Rácz K, Hunyady L and Patócs A: Crosstalk between TGF-β signaling and the microRNA machinery. Trends Pharmacol Sci. 33:382–393. 2012. View Article : Google Scholar : PubMed/NCBI
28	Fu RQ, Hu DP, Hu YB, Hong L, Sun QF and Ding JG: miR-21 promotes α-SMA and collagen I expression in hepatic stellate cells via the Smad7 signaling pathway. Mol Med Rep. 16:4327–4333. 2017.PubMed/NCBI